The U.S. is in the midst of a dark period for the COVID-19 pandemic. Hospitalizations and positive case numbers are at record levels and while daily death counts have not hit the peaks we saw last summer, there are other long-term effects from this disease that have yet to be fully recognized. This comes amid a wave of optimism coming on the vaccine development front with more than 70 different vaccine trials currently underway. Today on Insight, vaccine development, who will have priority, and how it could change our lives.
- The New York Times Columnist and "A Planet of Viruses" Author Carl Zimmer on the digital "Vaccine Tracker" set up by the Times to show the status of various coronavirus trials
- California State Senator Richard Pan explains vaccine priority with people of color and how people of color have been disproportionately affected by COVID-19
- Illumina Senior Vice President & Chief Technology Officer Alex Aravanis discusses the technology his company made to sequence the SARS-CoV-2 virus, which is the basis for all of the vaccines showing promising results
- AFAR Media Travel News Editor Michelle Baran on how the forthcoming coronavirus vaccines will affect travel and possible complications with the rollout that travelers should consider